AMED: the cashflow

MyFinsight

For the quarter ending 2025-06-30, AMED had $34,062K increase in cash & cash equivalents over the period. $61,609K in free cash flow.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-06-30
Non-cash compensation	14,749
Net income	90,873
Other current assets	-3,576
Other assets	-48
Other long-term obligations	-34
Operating lease liabilities	-15,248
Accrued expenses	-15,666
Patient accounts receivable	-554
Accounts payable	-9,805
Equity in earnings from equity method investments	3,435
Gain on disposal of property and equipment	45
Gain on equity method investment	48,093
Return on equity method investments	3,379
Depreciation and amortization (inclusive of depreciation included in cost of service)	13,488
Deferred income taxes	16,395
Impairment	883
Amortization of deferred debt issuance costs	442
Operating lease right of use assets	-2,364
Gain on termination of joint venture	3,568
Amortization and impairment of operating lease right of use assets	17,395
Net cash provided by operating activities	63,524
Proceeds from the sale of deferred compensation plan assets	27
Proceeds from the sale of property and equipment	19
Investments in technology assets	426
Purchases of property and equipment	1,915
Investment in equity method investee	0
Net cash used in investing activities	-2,295
Principal payments of long-term obligations	19,552
Proceeds from issuance of stock upon exercise of stock options	149
Noncontrolling interest contributions	0
Shares withheld to pay taxes on non-cash compensation	6,005
Debt issuance costs	499
Noncontrolling interest distributions	1,260
Net cash used in financing activities	-27,167
Net increase in cash, cash equivalents and restricted cash	34,062

Unit: Thousand (K) dollars